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IN VIVO EVIDENCE THAT THE RISE IN PLASMA 
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BY IL l@ 
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Although it has often been speculated that Interleukin (IL) la and IL I@ are circulating 
endogenous pyrogens (EP), there are few data demonstrating an elevation of these cytokines in 
the plasma of febrile animals. We hypothesized that IL 1 is released locally and may act to 
stimulate the release of another pyrogen, IL 6, which circulates to the brain to cause fever. The 
major purpose of the present study was to determine whether pretreatment of rats with antiserum 
to IL l/3, which attenuates lipopolysaccharide (LPS) induced fever, also results in an attenuation 
of the rise in plasma and cerebrospinal fluid (CSF) concentrations of IL 6. Our results show that 
injection of IL 18 produced dose-dependent rises in temperature and increases in plasma and 
CSF IL 6 activity, and that pretreatment of rats i.v. with antiserum to IL l/3 produced a 55% 
decrease in the fever caused by LPS injection, a 68 % decrease in plasma IL 6, and a 67% 
decrease in CSF IL 6. These data confirm the findings of previous studies that IL 18 is required 
for a portion of LPS-induced fever and also provide the first in vivo demonstration that the rise of 
IL 6 in rats injected with a fever-inducing dose of LPS can be significantly blocked by antiserum 
to IL l/l. Overall, the data in our study can be interpreted as being consistent with the hypothesis 
that the pyrogenic effect of IL 1B is mediated mainly through the release of IL 6, but conclusive 
confirmation of this hypothesis must await studies with antibodies to IL 6. 
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Over the past decade, it has been hypothesized that 
Interleukin (IL) lor and/or IL Ifi are circulating endog- 
enous pyrogens (EP). IL 1 meets several of the criteria 
for an endogenous pyrogen: (1) recombinant human 
(rh) and murine (rm) IL lor and IL lp are capable of 
inducing fever in rat and rabbitImg; (2) rh IL 1 can 
stimulate the release of prostaglandin E,, which is 
believed to be a neural mediator that increases the 
temperature set-point10T’4; (3) antiserum to IL 10 atten- 
uates LPS fever in the rat. 15-16 Since antiserum to IL lol 
did not attenuate the LPS fever,15,17 these data are 
consistent with the hypothesis that IL lfi, but not IL la, 
is an endogenous pyrogen. There are, however, few data 
demonstrating an elevation of either form of IL 1 in the 
plasma of febrile animals. However, another putative 
endogenous pyrogen, IL 6,‘*-” not only caused pros- 
taglandin-dependent fevers upon injection into animals, 
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but also increased markedly in the plasma and cerebrospi- 
nal fluid (CSF) of LPS-injected rats.” In that study, 
there was a strong correlation between either the plasma 
or CSF IL 6 activity and fever. Because the release of IL 
6 can be stimulated by IL l/3 both in vivo and in 
vitro,2’-22 we hypothesized that IL 1 is released locally in 
response to LPS and may act to stimulate the release of 
another pyrogen, IL 6, which circulates to the brain to 
cause fever. 
The purpose of the present study was to determine 
in the rat: (A) whether injection of fever-inducing doses 
of IL 18 cause a rise in plasma and CSF concentrations 
of IL 6, (B) whether pretreatment with antiserum to IL 
l/3, which attenuates LPS-induced fever, also results in 
an attenuation of the rise in plasma and CSF concentra- 
tion of IL 6 in response to injection of LPS, and (C) 
whether there is a correlation between LPS-induced 
fever and the plasma and CSF concentration of IL 6 in 
rats treated with antiserum to IL 10. 
Experimental Protocols 
Protocol 1. Injection of Recombinant Mouse IL 
lp and Saline. Recombinant mouse IL 10 was in- 
jected intraperitoneally (i.p.) in doses of 0.75, 1.5,3 and 
6 pg/kg dissolved in a total volume of 1 mL 
199 
200 / LeMay et al. CYTOKINE, Vol. 2, No. 3 (May 1990: 199-204) 
saline/kg. Control rats were injected with the same 
volume of saline. Blood and CSF were collected at 4 hr 
after the injection. 
Protocol 2. Injection of LPS into the rats that were 
previously treated with antiserum to IL lp and control 
serum. The antiserum to mouse IL I@ or the control 
serum was injected into anesthetized rats through the 
penis vein (i.v.) in a dose of 400 PI/rat 40 hr before the 
administration of LPS. LPS was injected intraperito- 
neally (i.p.) at a dose of 10 gg/kg dissolved in a total 
volume of 1 mL saline/kg. Blood and CSF were col- 
lected at 4 hr after the injection of saline or 10 pg/kg 
LPS. 
Data Analysis 
Data are presented as means f SE. Statistical 
differences among group means were determined for 
plasma and CSF IL 6 activities in the IL I/3 injection 
study using ANOVA. Statistical differences between 
any two group means were determined using Student’s 
t-tests, corrected for multiple comparisons by the method 
of Bonferroni whenever necessary. The P value of the 
correlations between body temperature and IL 6 was 
determined by logarithmic regression analysis. 
RESULTS 
Protocol 1. Injection of Recombinant Mouse IL 
l/3 and Saline. The thermal responses of rats to i.p. 
injection of various doses of rm IL lp are shown in Fig. 
1. The initial temperature increase during the first hour 
in all groups is a nonspecific transient effect seen 
following injection of any substance i.p. in the rat. After 
this first hour, in the groups injected with 0.75 pg/kg 
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Figure 1. Change in core temperature of rats after i.p. injection of 
either saline or one of four doses (0.75,1.25,3, and 6 gg/kg in saline) of 
recombinant mouse IL 18. 
Injection occurred at time 0. Temperatures at time 0 for the five 
groups were not significantly different from each other and averaged 
37.3OC. n = sample size. For clarity, not all Standard Error bars are 
illustrated. 
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Figure 2. Plasma and CSF IL 6 activity in rats injected with either 
saline or one of four doses (0.75, 1.25, 3, and 6 fig/kg in saline) of 
recombinant mouse IL 18. 
Blood samples were collected at 4 hr after the injection in the rats 
whose temperature changes are shown in Fig. 1. Sample size is 
indicated in parentheses. 
and 1.5 pg/kg of recombinant mouse IL l& a small rise 
(approximately 0.5%) in body temperature occurred. In 
the groups injected with 3 pg/kg and 6 pg/kg of 
recombinant IL l/3, the temperature started to rise more 
markedly after 90 min, and reached a peak of about 
1.8“C at about 200 min (P = 0.0014, ANOVA with 
repeated measurement). 
We also measured the IL 6 activities in plasma and 
CSF in these same rats 4 hr following i.p. injection with 
saline or IL l@ (Fig. 2). In control (saline-injected) 
animals, plasma and CSF IL-6 were 14 f 14 and 0 
U/mL respectively. Following injection of 0.75 pg IL 
lp/kg, IL 6 activity was 214 i 53 U/mL in plasma and 
62 i: 19 U/m in CSF. Following injection of 6 pg IL 
l@/kg, IL 6 activity was 1,230 + 138 U/mL in plasma 
and 578 + 109 U/mL in CSF. Both plasma and CSF IL 
6 activity increased significantly as the dose of recombi- 
nant mouse IL l@ was increased (P = 0.0001, ANOVA). 
Protocol 2. Injection of LPS Into the Rats That Were 
Previously Treated With Antiserum to IL l@ and Control 
Serum. The mean change in core temperature of rats 
after i.p. injection of saline or 10 Fg LPS/kg in groups of 
rats treated 40 hr earlier with either control serum or 
antiserum to IL lp is shown in Fig. 3. These tempera- 
ture data are the mean changes seen from 120 min to 
240 min following the injection of saline or LPS. There 
were no significant differences in the changes of core 
temperature between the saline-anti-IL l@ serum and 
saline-control serum groups (P = 0.54). The changes in 
body temperature, following injection of LPS, were 
significantly lower in the group receiving antiserum to 
IL 1P (0.54 1: 0.12%) than in the control-serum treated 
group (1.19 + O.ll°C) (P = 0.0008). There was no 
significant difference in core temperature changes be- 
tween the saline-anti-IL lb serum and LPS-anti-IL ID 
serum groups (P = 0.84). Although the changes in body 
temperature following injection of LPS were signifi- 
cantly lower in the rats receiving antiserum to IL 10, 
neither the rise of body temperature from the injection 
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Figure 3. Mean change in core temperature of rats after i.p, injection 
of saline or LPS in groups of rats previously treated with either control 
serum or antiserum to IL lb. 
Sample size is indicated in parentheses. These temperature data are 
the mean values occurring from 120 min to 240 min following the i.p. 
injection of saline or LPS. 
(stress hyperthermia) nor the circadian night-time rise 
of body temperature were altered by the antiserum to IL 
l@ (data not shown). 
Fig. 4 shows the plasma IL 6 data in these animals 4 
hr after injection of saline or LPS. After injection of 
saline, plasma IL 6 activity was 119 -+ 4 U/mL in the 
group treated with antiserum to IL l/3 and 44 f 25 
U/mL in the control serum group. Following injection of 
10 pg/kg of LPS, plasma IL 6 activity was 15,964 rf: 
8,940 U/mL in the antiserum-treated group and 
50,184 + 14,771 U/mL in the control-serum group 
(P = 0.03). 
Fig. 5 shows the 4 hr CSF IL 6 data for the same 
rats as in Fig. 4. After injection of saline, CSF IL 6 
activity was 30 + 28 U/mL in the antiserum-treated 
group and 17 + 9 U/mL in the control serum group. 
Following injection of 10 pg/kg LPS, CSF IL 6 activity 
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Figure 4. Plasma IL 6 activity in rats injected with (1) antiserum to IL 
l/3 plus saline, (2) control serum plus saline, (3) antiserum to IL 18 plus 
10 pg/kg LPS, and (4) control serum plus 10 ag/kg LPS. 
Plasma samples were collected at 44 hr after injection of control serum 
or antiserum to IL 10 (400 cl/rat) and 4 hr after injection of saline or 
LPS (10 pg/kg). Sample size is indicated in parentheses. P values 
were calculated by comparing the group of rats injected with control 
serum plus 10 pg/kg LPS to the group of rats injected with antiserum 
to IL 10 plus 10 pg/kg LPS using a Student’s t-test. 
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Figure 5. CSF IL 6 activity in rats injected with (1) antiserum to IL 
18 plus saline, (2) control serum plus saline, (3) antiserum to IL lj3 plus 
10 bg/kg LPS, and (4) control serum plus 10 ag/kg LPS. 
CSF samples were collected at 44 hr after injection of control serum or 
antiserum to IL lp (400 pi/rat) and 4 hr after injection of saline or 
LPS (10 Fg/kg). Sample size is indicated in parentheses. P values 
were calculated by comparing the group of rats injected with control 
serum plus 10 pg/kg LPS to the group of rats injected with antiserum 
to IL l@ plus 10 pg/kg LPS using a Student’s t-test. 
was 292 c 146 U/mL in the antiserum treated group 
and 877 + 251 U/mL in the control serum group 
(P = 0.028). 
The quantitative relationships between IL 6 and 
changes in body temperature at 120 min to 240 min 
post-injection for each individual rat are shown in Fig. 6 
and Fig. 7. The correlation coefficient relating IL 6 
activity and body temperature, based on a logarithmic 
regression, was 0.74 (P < 0.0062) for plasma and 0.75 
(P -c 0.0003) for CSF. 
Fig. 8 shows the result of the IL 6 recovery study in 
plasma from LPS-treated animals. There is no indica- 
tion of any factors present in the plasma of control or 
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Figure 6. Plasma IL 6 activity vs change in body temperature for rats 
injected with control serum plus 10 pg/kg LPS or with antiserum to IL 
l/3 plus 10 fig/kg LPS. 
The data used are the same as those from Figs. 3 and 4 and are for 
individual rats at the relevant time. r = correlation coefficient, which 
was calculated based on best-fit logarithmic regression, and P = level 
of statistical significance. 
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Figure 7. CSF IL 6 activity vs change in body temperature for rats 
injected with control serum plus 10 pug/kg LPS or with antiserum to IL 
l/3 plus 10 /&kg LPS. 
The data used are the same as those from Figs. 3 and 5 and are for 
individual rats at the relevant time. r = correlation coefficient, which 
was calculated based on best-fit logarithmic regression, and P = level 
of statistical significance. 
LPS-treated animals that inhibit or facilitate the B-9 
assay. Identical results were obtained from recovery 
studies done in the plasma of IL l&treated animals 
(data not shown). 
DISCUSSION 
Our data qualitatively support the hypothesis that 
during LPS fever IL lp is released locally and may act 
to stimulate the release of another pyrogen, IL 6, which 
circulates to the brain to cause fever. Injection of fever 
producing doses of rm IL l@ resulted in significant 
increases in both the plasma and CSF IL 6 concentra- 
tions and in body temperature. Approximately two- 
thirds of the rise of core temperature and rise of IL 6 in 
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Figure 8. Change in IL 6 activity from base line after addition of 
known quantities of rh IL 6. 
Rat plasma was harvested 4 hr after injection of either saline or 10 
pg/kg LPS. Base values were 80 U/mL for the saline group and 
88,000 U/mL for the LPS treated group. The tissue culture medium 
was free of IL 6, and so the baseline value was 0. 
LPS fever was blocked by pretreatment with antiserum 
to IL lp. There was a positive correlation between the 
changes in plasma and CSF IL 6 and body temperature 
in these experiments. 
However, quantitatively, the data pose a problem 
for this hypothesis. The plasma IL 6 (1,230 U/mL) in 
IL l/3 fever was much lower than the plasma IL 6 
(50,184 U/mL) in LPS fever, but the magnitude of the 
IL l/3 fever was similar to the magnitude of the LPS 
fever. LPS induces the release of IL lp and TNF, and 
there is a known synergy between these two cytokines in 
inducing the production of IL 6.23 This synergy may 
account for our finding higher IL 6 levels with LPS than 
with IL lp alone. Whatever the explanation, the impor- 
tant point, which casts doubt on the hypothesis that IL 6 
is the major circulating pyrogen in LPS fever, is that the 
fevers induced by LPS and IL 10 were similar, even 
though the plasma IL 6 levels were very different. 
We speculate several possible explanations for this 
quantitative discrepancy. The first possibility is that the 
hypothesis is wrong, that plasma IL 6 is not the mediator 
of LPS fever, and that IL lp results in fever directly or 
through other circulating cytokines (e.g., NAF/IL 8, or 
MIP-l), without the participation of circulating IL 6. 
Further evidence, which is consistent with IL 6 not being 
the major pyrogen in LPS fever, comes from studies 
demonstrating that anti-tumor necrosis factor (anti- 
TNF) antibody enhanced rather than reduced fever16,2g 
and that anti-TNF antibody suppressed rather than 
enhanced IL 6 production.23 These results together 
imply that the fever enhancement with anti-TNF anti- 
body occurred in the face of decreased IL 6 levels, and 
such results call into question a major role for IL 6 as a 
pyrogen in LPS-induced fever. 
A second possibility, one that preserves a major 
pyrogenic role for IL 6 in LPS fever, is that it is the 
concentration of IL 6 in the brain rather than in the 
plasma that is important for the development of fever. 
This possibility is raised by the fact that, despite the 
quantitative discrepancy between plasma IL 6 values 
after LPS and IL l/3, the value of CSF IL 6 (578 U/mL) 
in IL l/3 fever was close to the value of CSF IL 6 (877 
U/mL) measured during LPS fever. A recent study 
showed that hypothalamic tissue can release IL 6. This 
supports the hypothesis that the rise of IL 6 can come 
directly from the brain.*’ Therefore, it is possible that 
locally released IL l@ stimulates the release of IL 6 in 
brain tissue and that it is this IL 6 that causes fever. 
A third possibility, one that also preserves a major 
pyrogenic role for IL 6 in LPS fever, is that when large 
amounts of IL lb are injected systemically, a high 
concentration of circulating IL I/? is created that per- 
mits sufficient quantities of circulating IL lp to reach 
the brain and cause fever by a direct action on the 
hypothalamus, without involvement of IL 6. In contrast, 
this situation probably does not occur during LPS fever, 
because there are few data demonstrating an elevation 
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of IL l/3 in the plasma of febrile animals. In other words, 
it is possible that the fever caused by LPS may be 
entirely the result of the direct action on the brain of IL 
6 alone, while the fever caused by injection of IL l@ 
reflects the combined action of circulating IL 16 and IL 
6 on the central nervous system. 
The above three possibilities cannot be distin- 
guished by the present data, and a definitive answer to 
the hypothesis that IL 6 is the mediator of LPS fever 
awaits experiments using antibodies to IL 6. 
Finally, it should be emphasized that, to the best of 
our knowledge, these data provide the first evidence that 
the rise of IL 6 in LPS fever in vivo can be blocked 
significantly by antiserum to IL l/3, and supports the 
hypothesis that much of the rise in plasma IL 6 during 
LPS fever is stimulated by IL l/3. 
MATERIALS AND METHODS 
Animals 
Fifty specific-pathogen-free male Sprague-Dawley rats 
weighing 180 to 220 g were obtained from Charles River 
(Portage, MI). Rats were housed at 23 to 2S°C with a 12/ 12 hr 
light-dark cycle and given ad libitum tap water and rodent 
chow. 
Measurement of Body Temperature 
Core temperature was measured by biotelemetry, using 
transmitters implanted intraperitoneally (i.p.) (Mini Mitter, 
Inc., Sunriver, OR). x The transmitters were implanted at 
least 4 days before the experiments. Each transmitter was 
calibrated before implantation. Output (frequency in Hz) was 
monitored by a mounted antenna placed under each rat’s cage 
and fed into a peripheral processor (Dataquest III system, 
Mini Mitter, Inc.) connected to an IBM-PC. Temperatures 
were recorded at 5 min intervals. To avoid any circadian 
variation in body temperature or plasma IL 6 activity, all 
injections were made between 8:00 AM and 10:00 AM, except 
for the injections of control serum or antiserum to IL l& which 
were at 5 PM. 
IL 6 Bioassay 
IL 6 activity in plasma and CSF was measured using the 
IL 6-dependent B-9 hybridoma cell line.27-29 The B-9 cells were 
cultured in Iscove’s modified Dulbecco’s medium (IMDM; 
Life Technology, Inc.) supplemented with human recombi- 
nant IL 6 (8 U/mL obtained from Dr. Gordon Wong, Genetics 
Institute), 20 PM 2-mercaptoethanol, 10% heat-inactivated 
fetal calf serum (FCS), 100 IU/mL penicillin and 100 yg/mL 
streptomycin. Cells were washed once in the above medium 
without added IL 6, before the addition of the plasma samples 
or known amounts of human rIL 6. 
To run the IL 6 assay, a 5 ~1 sample to be assayed was 
combined with 5000 B9 cells in 195 ~1 IMDM/lO% FCS in 
flat-bottom microtiter plates (Corning) for a final volume of 
200 ~1. All samples were run in duplicate. The control medium, 
which contained no IL 6, was run in quadruplicate. In addition 
to the undiluted plasma samples, a serial dilution of each 
sample was assayed. Serial dilution was performed because 
our standard curve indicated that high levels of IL 6 result in 
an inhibition of growth of the B-9 cells. Each sample was 
serially diluted initially to a maximum of 1:62,500. 
Cells were pulsed at 68 to 72 hr with 0.5 uCi 3H 
thymidine, harvested 4 hr later onto glass fiber filter strips 
(Cambridge Technology, Inc), and the radioactivity incorpo- 
rated into DNA was counted by a P-Scintillation Counter 
(Packard Instrument Company). For each assay, a standard 
curve was run with recombinant human IL 6. One unit of IL 6 
is equal to the amount that caused half-maximum prolifera- 
tion in the standard curve. From this standard curve, a best-fit 
regression was calculated for the rising portion of the curve in 
the linear range. The equation for this best fit line was used to 
calculate IL 6 activity in plasma samples. 
All samples were serially diluted until they became 
undetectable. All counts per minute (cpm) that fell within 2 
standard deviations of the baseline cpm were excluded to 
reduce the potential error resulting when converting IL 6 from 
cpm to units, by multiplying by the dilution factor. The largest 
calculated IL 6 activity, which fell outside two standard 
deviations of the baseline and fell well below the peak, was 
taken as the IL 6 value. This ensured that all data used fell on 
the steep linear portion of the standard curve, which increased 
the accuracy of the value. 
We also ran rh IL 6 from National Biological Standards 
Board (NBSB) in the B-9 assay to compare the units obtained 
from our B-9 assay and units from NBSB (Dr. Craig Rey- 
nolds, National Cancer Institute, Md.). This comparison 
indicated that 1 U of NBSB IL 6 is equal to approximately 300 
U in the B-9 assay. In other words, approximately 0.0034 
NBSB U were required to produce half maximal proliferation 
of the B-9 assay. In this paper, all units refer to the B-9 assay 
half-maximum units. 
Antiserum to IL l/3 and LPS 
Recombinant mouse IL l/3 and rabbit antiserum to mouse 
IL l/3 were obtained from Pfizer Research, Groton, CT. The 
specific activity of recombinant IL l/3 was 9 x 10’ U/mg based 
on lymphocyte activating factor assay (LAF). The antiserum 
to mouse IL l/I was made from rabbits immunized with 
murine recombinant IL l/3 (Daumy et al., submitted for 
publication). The resulting antibody was found to be specific 
for both mouse and rat IL l/3 by Western blotting. Blocking 
antibody was titered in vitro against recombinant murine IL 
l/3 using the LAF assay, and it was found that 2 pg of antibody 
would neutralize 1 ng of IL 1. Approximately 4 mg of antibody 
were administered per rat in each in vivo blocking experiment. 
Purified LPS (E. coli endotoxin 011 l:B4 # L 97F-4089) 
was obtained from Sigma Company. 
CSF and Plasma Samples 
To collect fluids, rats were anesthetized by intramuscular 
injection of a combination of 70 mg/kg ketamine hydrochlo- 
ride and 10 mg/kg xylazine. Blood was then collected 
within 1.5 min in a heparinized syringe by cardiac puncture. 
Plasma was separated by centrifugation of the freshly drawn 
blood and stored at -20°C. Immediately after the blood 
sample was collected, about 60 ~1 to 100 ~1 of CSF was drawn 
from the cisterna magna into a 0.5 mL syringe through a 28 
gauge Y2 inch needle. The percent of contamination of the CSF 
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with blood was estimated by visually comparing the color of 
tubes containing artificial CSF, which were serially diluted 
following the addition of a known amount of blood. In virtually 
all of the samples, the level of contamination was 0.001 parts of 
blood or lower. The actual CSF IL 6 activity was calculated by 
subtracting the IL 6 activity in the blood multiplied by the 
contamination factor from the measured IL 6 activity in the 
CSF. 
IL 6 Recovery 
We tested whether, after LPS and IL 10 injection, there 
were any factors present in the plasma sample that inhibited or 
enhanced the B-9 assay. We added known quantities of rh IL 6 
to the plasma samples obtained from rats at 4 hr following 
injection of sterile pyrogen free 0.9% sodium chloride (saline), 
IL l/3, or 10 pg/kg LPS and then ran the B-9 assay to 
determine the amount of IL 6 recovered from these samples. 
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